| 230.56 -5.61 (-2.38%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 274.36 |
1-year : | 284.19 |
| Resists | First : | 234.9 |
Second : | 243.32 |
| Pivot price | 234.17 |
|||
| Supports | First : | 221.28 |
Second : | 184.11 |
| MAs | MA(5) : | 231.51 |
MA(20) : | 234.33 |
| MA(100) : | 197.02  |
MA(250) : | 161.1 |
|
| MACD | MACD : | 3.8 |
Signal : | 5.6 |
| %K %D | K(14,3) : | 41.3 |
D(3) : | 37.3 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 243.32 | Low : | 105 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ JAZZ ] has closed above bottom band by 28.3%. Bollinger Bands are 21.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 236.69 - 238.05 | 238.05 - 239.27 |
| Low: | 226.95 - 228.42 | 228.42 - 229.74 |
| Close: | 228.45 - 230.8 | 230.8 - 232.92 |
Jazz Pharmaceuticals plc is a global biopharmaceutical firm dedicated to discovering, advancing, and bringing to market innovative medicines for conditions where treatment options are lacking, serving patients across the United States, Europe, and other international regions. Its extensive portfolio of both commercialized therapies and development candidates primarily focuses on neuroscience, particularly sleep disorders and movement conditions, alongside oncology, addressing both hematologic (blood) cancers and solid tumors. Among its principal marketed products are Xyrem, an oral solution managing cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients aged seven and older; Sunosi, also for EDS but in individuals with narcolepsy and obstructive sleep apnea; Erwinaze, targeting acute lymphoblastic leukemia; Defitelio, which treats hepatic veno-occlusive disease in adults and children; Vyxeos liposome for injection, indicated for adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca, prescribed for adult patients with metastatic small cell lung cancer. The company's developmental pipeline features Xywav, an oxybate candidate intended for EDS and cataplexy linked to narcolepsy, as well as idiopathic hypersomnia; JZP-324, a low-sodium oxybate formulation aiming to offer a significant alternative for narcolepsy patients; JZP385, a T-type calcium channel modulator being explored for essential tremor; JZP458, a recombinant Erwinia asparaginase used in multi-agent chemotherapy for both pediatric and adult patients; and JZP150, a compound under investigation for post-traumatic stress disorder. Jazz Pharmaceuticals maintains strategic licensing and collaborative partnerships with entities such as ImmunoGen, Inc., Codiak BioSciences, Inc., Pfenex, Inc., XL-protein GmbH, and Redx Pharma plc. Established in 2003, Jazz Pharmaceuticals plc operates from its headquarters in Dublin, Ireland.
Mon, 15 Jun 2026
Jazz Pharma announces late-stage trial setback for lung cancer therapy - MSN
Fri, 12 Jun 2026
Insider Sell: Neena Patil Sells Shares of Jazz Pharmaceuticals P - GuruFocus
Fri, 12 Jun 2026
[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity - Stock Titan
Fri, 12 Jun 2026
Jazz Pharmaceuticals lung cancer drug fails main trial goal - Reuters
Fri, 12 Jun 2026
Jazz Pharmaceuticals stock falls after lung cancer trial fails - Investing.com
Fri, 12 Jun 2026
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 108.5 (%) |
| Shares Short | 4,850 (K) |
| Shares Short P.Month | 5,240 (K) |
| EPS | 0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 70.29 |
| Profit Margin | 0.6 % |
| Operating Margin | 23.5 % |
| Return on Assets (ttm) | 6.9 % |
| Return on Equity (ttm) | 0.6 % |
| Qtrly Rev. Growth | 19.1 % |
| Gross Profit (p.s.) | 64.71 |
| Sales Per Share | 70.76 |
| EBITDA (p.s.) | 32.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,330 (M) |
| Levered Free Cash Flow | 1,340 (M) |
| PE Ratio | 1921.33 |
| PEG Ratio | 0.9 |
| Price to Book value | 3.28 |
| Price to Sales | 3.25 |
| Price to Cash Flow | 10.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|